

Tymlos (abaloparatide)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

☐ **URGENT**

MEMBER INFORMATION		
LAST NAME:		FIRST NAME:
PHONE NUMBER:		DATE OF BIRTH:
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

☐ MALE ☐ FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [PRIMETHERAPEUTICS.COM/NOPP](https://primetherapeutics.com/nopp)

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION	
LAST NAME:	FIRST NAME:
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:
NPI NUMBER:	DEA NUMBER:
PHONE NUMBER:	FAX NUMBER:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page.

Tymlos (abaloparatide)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE): 	DURATION OF THERAPY (SPECIFY DATES): 	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
<input type="checkbox"/> Hypogonadal osteoporosis <input type="checkbox"/> Idiopathic osteoporosis <input type="checkbox"/> Osteoporosis associated with systemic glucocorticoid therapy <input type="checkbox"/> Postmenopausal osteoporosis <input type="checkbox"/> Severe osteoporosis <input type="checkbox"/> Other diagnosis: _____ ICD-10 _____		
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
<p>Has the patient had prior treatment with Forteo (teriparatide)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Has the patient ever been treated with a bisphosphonate? <input type="checkbox"/> Yes <input type="checkbox"/> No Please provide documentation.</p> <p>Does the patient have reflux/GERD OR severe renal disease, as defined by a CrCl less than 35 mL/min? * <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Please provide documentation.</p> <p>Has the patient failed previous treatment with at least one bisphosphonate (i.e., Fosamax [alendronate], Actonel [risedronate], Boniva [ibandronate], or Reclast [zoledronic acid])? <input type="checkbox"/> Yes <input type="checkbox"/> No Please provide documentation.</p> <p>Has the patient been intolerant to previous treatment with at least one bisphosphonate (i.e., Fosamax [alendronate], Actonel [risedronate], Boniva [ibandronate], or Reclast [zoledronic acid])? * <input type="checkbox"/> Yes <input type="checkbox"/> No Please provide documentation.</p> <p>Was the treatment failure measured by a decline in bone mineral density in g/cm2 of greater than or equal to 3% in the spine and/or hip while on bisphosphonate therapy? * <input type="checkbox"/> Yes <input type="checkbox"/> No Please provide documentation.</p> <p>Was the treatment failure due to a fracture while being treated with bisphosphonate therapy and did this fracture occur in the past 3 years?* <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Does patient have a diagnosis of severe osteoporosis with very high fracture risk? <input type="checkbox"/> Yes <input type="checkbox"/> No Please provide documentation.</p> <p>Does patient have a very low T-score (eg, T-score of ≤ -3.0) even in the absence of fracture(s)? <input type="checkbox"/> Yes <input type="checkbox"/> No Please provide documentation.</p> <p>Does patient have a T-score of ≤ -2.5 plus a fragility fracture? <input type="checkbox"/> Yes <input type="checkbox"/> No Please provide documentation.</p> <p>Does patient have severe or multiple vertebral fractures? <input type="checkbox"/> Yes <input type="checkbox"/> No Please provide documentation.</p> <p>Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?</p>		

Tymlos (abaloparatide)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201

P.O. Box 64811

St. Paul, MN 55164-0811